Full Year 2024 H Lundbeck A/S Earnings Call Transcript
Key Points
- H. Lundbeck AS (HLUBF) reported a record revenue of DKK22 billion for 2024, marking a 14% growth at constant exchange rates.
- Strategic brands, including Rexulti and Vyepti, showed strong performance with a 21% growth, contributing significantly to the company's revenue.
- The company has a robust pipeline with late-stage developments, including the progression of bexicaserin and anti-PACAP programs.
- Vyepti's global net revenue grew by 72% year-on-year, with strong adoption in both the US and international markets.
- The company maintains a healthy financial dynamic with an adjusted EBITDA margin greater than 30%, despite increased R&D investments.
- H. Lundbeck AS (HLUBF) faced increased administrative expenses due to high legal provisions for ongoing litigations.
- R&D costs rose by 30%, reaching DKK4.5 billion, driven by investments in new programs and an impairment loss recognized in Q3 2024.
- The company anticipates generic competition for Brintellix in Canada and Abilify in Europe, which could impact future revenue.
- There was some destocking observed for both Rexulti and Vyepti, affecting inventory levels and potentially impacting short-term sales figures.
- The effective tax rate dropped significantly to 15.5%, which may not be sustainable in the long term, affecting future profitability.
/- -
Thank you, everyone, and thank you for joining, of course, today's call. It's my pleasure to be able to present to you the 2024 full year results, which we see as a transformative year for Lundbeck and of course, also provide you with guidance for 2025, which reflects really the confidence in our strategy as a focused innovator. So if we go to the next slide, again, today, of course, is subject to forward-looking statements and subject to change.
If we can go to the next slide, please. So as I opened up with my comments, I see this as really as a transformative year for Lundbeck. 12 months ago, we introduced the focused innovative strategy. There are three pillars: one of growth, pipeline and funding of that future in growth and innovation.
And I would say today, when you look at '24, the growth is a record year for Lundbeck. The pipeline has fundamentally changed over the last 12 months with a profile of more late stage. And with the funding that we are generating through
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
